Literature DB >> 34326133

Location of Gastrointestinal Stromal Tumor (GIST) in the Stomach Predicts Tumor Mutation Profile and Drug Sensitivity.

Ashwyn K Sharma1,2, Jorge de la Torre1,2, Nikki S IJzerman3,4, Thomas L Sutton5, Beiqun Zhao1,2, Tahsin M Khan6, Sudeep Banerjee1,2,7, Christina Cui1, Vi Nguyen1, Maha Alkhuziem1,2, Petur Snaebjornsson8, Hester van Boven8, Annemarie Bruining9, Chih-Min Tang1,2, Hyunho Yoon1,2, Alexa De la Fuente1, Shumei Kato2,10, Hitendra Patel2,10, Michael C Heinrich11, Christopher L Corless12, Santiago Horgan13, Adam M Burgoyne2,10, Paul Fanta2,10, Jill P Mesirov2,14, Andrew M Blakely6, Jeremy L Davis6, Skye C Mayo5, Winan J van Houdt15, Neeltje Steeghs3, Jason K Sicklick1,2.   

Abstract

PURPOSE: Gastrointestinal stromal tumors (GIST) commonly arise in different regions of the stomach and are driven by various mutations (most often in KIT, PDGFRA, and SDHx). We hypothesized that the anatomic location of gastric GIST is associated with unique genomic profiles and distinct driver mutations. EXPERIMENTAL
DESIGN: We compared KIT versus non-KIT status with tumor location within the National Cancer Database (NCDB) for 2,418 patients with primary gastric GIST. Additionally, we compiled an international cohort (TransAtlantic GIST Collaborative, TAGC) of 236 patients and reviewed sequencing results, cross-sectional imaging, and operative reports. Subgroup analyses were performed for tumors located proximally versus distally. Risk factors for KIT versus non-KIT tumors were identified using multivariate regression analysis. A random forest machine learning model was then developed to determine feature importance.
RESULTS: Within the NCDB cohort, non-KIT mutants dominated distal tumor locations (P < 0.03). Proximal GIST were almost exclusively KIT mutant (96%) in the TAGC cohort, whereas 100% of PDGFRA and SDH-mutant GIST occurred in the distal stomach. On multivariate regression analysis, tumor location was associated with KIT versus non-KIT mutations. Using random forest machine learning analysis, stomach location was the most important feature for predicting mutation status.
CONCLUSIONS: We provide the first evidence that the mutational landscape of gastric GIST is related to tumor location. Proximal gastric GIST are overwhelmingly KIT mutant, irrespective of morphology or age, whereas distal tumors display non-KIT genomic diversity. Anatomic location of gastric GIST may therefore provide immediate guidance for clinical treatment decisions and selective confirmatory genomic testing when resources are limited. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34326133      PMCID: PMC8799780          DOI: 10.1158/1078-0432.CCR-21-1221

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  20 in total

1.  Genomic spectra of biliary tract cancer.

Authors:  Hiromi Nakamura; Yasuhito Arai; Yasushi Totoki; Tomoki Shirota; Asmaa Elzawahry; Mamoru Kato; Natsuko Hama; Fumie Hosoda; Tomoko Urushidate; Shoko Ohashi; Nobuyoshi Hiraoka; Hidenori Ojima; Kazuaki Shimada; Takuji Okusaka; Tomoo Kosuge; Shinichi Miyagawa; Tatsuhiro Shibata
Journal:  Nat Genet       Date:  2015-08-10       Impact factor: 38.330

Review 2.  Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes.

Authors:  Michael S Lee; David G Menter; Scott Kopetz
Journal:  J Natl Compr Canc Netw       Date:  2017-03       Impact factor: 11.908

3.  Overcoming Cost Implications of Mutational Analysis in Patients with Gastrointestinal Stromal Tumors: A Pragmatic Approach.

Authors:  Patrick Schöffski; Agnieszka Wozniak; Oliver Schöffski; Liesbet van Eycken; Maria Debiec-Rychter
Journal:  Oncol Res Treat       Date:  2016-11-18       Impact factor: 2.825

4.  The Call of "The Wild"-Type GIST: It's Time for Domestication.

Authors:  Maha Alkhuziem; Adam M Burgoyne; Paul T Fanta; Chih-Min Tang; Jason K Sicklick
Journal:  J Natl Compr Canc Netw       Date:  2017-05       Impact factor: 11.908

Review 5.  Gastrointestinal stromal tumours: origin and molecular oncology.

Authors:  Christopher L Corless; Christine M Barnett; Michael C Heinrich
Journal:  Nat Rev Cancer       Date:  2011-11-17       Impact factor: 60.716

Review 6.  Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.

Authors:  Jason K Sicklick; Paul T Fanta; Kelly Shimabukuro; Razelle Kurzrock
Journal:  Cancer Metastasis Rev       Date:  2016-06       Impact factor: 9.264

7.  Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST).

Authors:  Marc Daniels; Irene Lurkin; Roland Pauli; Erhard Erbstösser; Uwe Hildebrandt; Karsten Hellwig; Uwe Zschille; Petra Lüders; Gabriele Krüger; Jürgen Knolle; Bernd Stengel; Friedrich Prall; Kay Hertel; Hartmut Lobeck; Brigitte Popp; Franz Theissig; Peter Wünsch; Ellen Zwarthoff; Abbas Agaimy; Regine Schneider-Stock
Journal:  Cancer Lett       Date:  2011-08-06       Impact factor: 8.679

8.  Low Frequency of Mutation Testing in the United States: An Analysis of 3866 GIST Patients.

Authors:  Jorge Florindez; Jonathan Trent
Journal:  Am J Clin Oncol       Date:  2020-04       Impact factor: 2.339

9.  Comprehensive molecular characterization of gastric adenocarcinoma.

Authors: 
Journal:  Nature       Date:  2014-07-23       Impact factor: 49.962

10.  Cost-effectiveness Analysis of Genetic Testing and Tailored First-Line Therapy for Patients With Metastatic Gastrointestinal Stromal Tumors.

Authors:  Sudeep Banerjee; Abhishek Kumar; Nicole Lopez; Beiqun Zhao; Chih-Min Tang; Mayra Yebra; Hyunho Yoon; James D Murphy; Jason K Sicklick
Journal:  JAMA Netw Open       Date:  2020-09-01
View more
  1 in total

Review 1.  New treatment strategies for advanced-stage gastrointestinal stromal tumours.

Authors:  Lillian R Klug; Homma M Khosroyani; Jason D Kent; Michael C Heinrich
Journal:  Nat Rev Clin Oncol       Date:  2022-02-25       Impact factor: 66.675

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.